牛牛AI助理已提取核心訊息
Zdravka Medarova, a United States citizen, has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC) on December 31, 2023, disclosing her ownership in TransCode Therapeutics, Inc. The filing indicates that Medarova beneficially owns 112,077 shares of TransCode Therapeutics' common stock, which represents approximately 0.4% of the company's outstanding shares. This ownership includes 96,639 shares held directly and 15,438 shares issuable upon the exercise of stock options within 60 days of the reporting date. The filing also notes that these figures do not account for a 1-for-40 reverse stock split that occurred on January 16, 2024. The Schedule 13G amendment was submitted to report that Medarova now owns less than 5% of TransCode Therapeutics, as indicated by the checked box in Item 5 of the filing.
Zdravka Medarova, a United States citizen, has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC) on December 31, 2023, disclosing her ownership in TransCode Therapeutics, Inc. The filing indicates that Medarova beneficially owns 112,077 shares of TransCode Therapeutics' common stock, which represents approximately 0.4% of the company's outstanding shares. This ownership includes 96,639 shares held directly and 15,438 shares issuable upon the exercise of stock options within 60 days of the reporting date. The filing also notes that these figures do not account for a 1-for-40 reverse stock split that occurred on January 16, 2024. The Schedule 13G amendment was submitted to report that Medarova now owns less than 5% of TransCode Therapeutics, as indicated by the checked box in Item 5 of the filing.
美國公民茲德拉夫卡·梅達羅娃已於2023年12月31日向美國證券交易委員會（SEC）提交了經修訂的附表13G，披露了她在TransCode Therapeutics, Inc.的所有權。該文件顯示，梅達羅娃實益擁有TransCode Therapeutics普通股的112,077股，約佔該公司已發行股份的0.4％。該所有權包括在報告日起60天內直接持有的96,639股股票和行使股票期權時可發行的15,438股股票。該文件還指出，這些數字並未考慮2024年1月16日發生的40比1的反向股票拆分。提交附表13G修正案的目的是報告說，梅達羅娃現在擁有TransCode Therapeutics不到5％的股份，如文件第5項中的複選框所示。
美國公民茲德拉夫卡·梅達羅娃已於2023年12月31日向美國證券交易委員會（SEC）提交了經修訂的附表13G，披露了她在TransCode Therapeutics, Inc.的所有權。該文件顯示，梅達羅娃實益擁有TransCode Therapeutics普通股的112,077股，約佔該公司已發行股份的0.4％。該所有權包括在報告日起60天內直接持有的96,639股股票和行使股票期權時可發行的15,438股股票。該文件還指出，這些數字並未考慮2024年1月16日發生的40比1的反向股票拆分。提交附表13G修正案的目的是報告說，梅達羅娃現在擁有TransCode Therapeutics不到5％的股份，如文件第5項中的複選框所示。
有用
沒用